Structure–activity relationship, <i>in vitro</i> and <i>in vivo</i> evaluation of novel dienyl sulphonyl fluorides as selective BuChE inhibitors for the treatment of Alzheimer's disease
作者:Chengyao Wu、Guijuan Zhang、Zai-Wei Zhang、Xia Jiang、Ziwen Zhang、Huanhuan Li、Hua-Li Qin、Wenjian Tang
DOI:10.1080/14756366.2021.1959571
日期:2021.1.1
Abstract To discover novel scaffolds as leads against dementia, a series of δ-aryl-1,3-dienesulfonyl fluorides with α-halo, α-aryl and α-alkynyl were assayed for ChE inhibitory activity, in which compound A10 was identified as a selective BuChE inhibitor (IC50 = 0.021 μM for eqBChE, 3.62 μM for hBuChE). SAR of BuChE inhibition showed: (i) o- > m- > p-; –OCH3 > –CH3 > –Cl (–Br) for δ-aryl; (ii) α-Br > α-Cl
抽象的 为了发现抗痴呆的新型支架,我们对一系列具有 α-卤素、α-芳基和 α-炔基的 δ-芳基-1,3-二烯磺酰氟进行了 ChE 抑制活性测定,其中化合物A10被鉴定为选择性BuChE 抑制剂(对于 eqBChE,IC 50 = 0.021 μM;对于 hBuChE,IC 50 = 3.62 μM)。 BuChE 抑制的 SAR 显示:(i) o - > m - > p -; –OCH 3 > –CH 3 > –Cl (–Br) 对于δ -芳基; (ii) α-Br > α-Cl、α-I。化合物A10表现出神经保护作用、BBB 渗透作用、对 BuChE ( K i = 29 nM) 的混合竞争抑制作用以及良性神经和肝脏安全性。 A10治疗几乎可以将Aβ1-42诱导的认知功能障碍完全恢复至正常水平,并且Aβ1-42总量的评估证实了其抗淀粉样蛋白生成特性。因此,潜在的BuChE抑制剂A10是治疗AD的有希望的有效先导药物。